HDAC inhibitors: Modulating leukocyte differentiation, survival, proliferation and inflammation

Immunology and Cell Biology

Volumn 90, Issue 1, 2012, Pages 14-22

  Sweet, Matthew J ^a   Shakespear, Melanie R ^a   Kamal, Nabilah A ^a   Fairlie, David P ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

apoptosis; histone deacetylase; immune cell; inhibitor; proliferation; survival

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BUTYRIC ACID; CASPASE 10; CASPASE 8; COLONY STIMULATING FACTOR 1; DEATH RECEPTOR 4; ENTINOSTAT; HEAT SHOCK PROTEIN 70; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; PROTEIN BAK; PROTEIN BAX; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; ROMIDEPSIN; SIRTUIN 1; TRICHOSTATIN A; VORINOSTAT;

ALLOGRAFT; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CANCER INHIBITION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL EXPANSION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY; GENE SILENCING; GRAFT SURVIVAL; HUMAN; IMMUNOREGULATION; INFLAMMATION; LEUKOCYTE; MACROPHAGE; MONOCYTE; NEUTROPENIA; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; THROMBOCYTOPENIA; THYMOCYTE; TUMOR CELL; TUMOR GROWTH;

ANTI-INFLAMMATORY AGENTS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; INFLAMMATION; ISOENZYMES; LEUKOCYTES;

EID: 84855448173     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.88     Document Type: Review

References (93)

1. Friend C, Scher W, Holland JG, Sato T. Hemoglobin synthesis in murinevirus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide. Proc Natl Acad Sci USA 1971; 68: 378-382.
2. Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW et al. Romidepsin: A new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther 2010; 10: 997-1008.
3. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007; 25: 84-90. (Pubitemid 46087907)
4. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769-784. (Pubitemid 44348499)
5. Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs 2010; 28(Suppl 1): S3-S20.
6. Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancerdrugs. Expert Opin Investig Drugs 2010; 19: 1049-1066.
7. Dinarello CA, Fossati G, Mascagni P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med 2011; 17: 333-352.
8. Halili MA, Andrews MR, Sweet MJ, Fairlie DP. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 2009; 9: 309-319.
9. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 2011; 32: 335-343.
10. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71-76. (Pubitemid 40215840)
11. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P et al. Tumor-selectiveaction of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005; 11: 77-84. (Pubitemid 40215841)
12. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007; 104: 8071-8076. (Pubitemid 47185877)
13. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98: 10833-10838. (Pubitemid 32878706)
14. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005; 102: 673-678. (Pubitemid 40282724)
15. Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y et al. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound beta-phenylethyl isothiocyanate. Blood 2010; 116: 2732-2741.
16. Gabrielli B, Chia K, Warrener R. Finally how histone deacetylase inhibitors disrupt mitosis!. Cell Cycle 2011; 10: 2658-26561.
17. Warrener R, Beamish H, Burgess A, Waterhouse NJ, Giles N, Fairlie D et al. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J 2003; 17: 1550-1552.
18. Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998; 95: 6791-6796.
19. Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N et al. Histonedeacetylase inhibition selectivelyalterstheactivityand expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 1999; 274: 34940-34947. (Pubitemid 129509542)
20. Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R et al. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004; 23: 6693-6701. (Pubitemid 39280001)
21. Roth P, Bartocci A, Stanley ER. Lipopolysaccharide induces synthesisof mousecolony-stimulatingfactor-1 in vivo. JImmunol1997; 158: 3874-3880. (Pubitemid 127488747)
22. Campbell IK, Rich MJ, Bischof RJ, Hamilton JA. The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and require-ment for endogenous M-CSF. J Leukoc Biol 2000; 68: 144-150.
23. Lenda DM, Kikawada E, Stanley ER, Kelley VR. Reduced macrophage recruitment, proliferation, and activation in colony-stimulating factor-1-deficient mice results in decreased tubular apoptosis during renal inflammation. J Immunol 2003; 170: 3254-3262. (Pubitemid 36302203)
24. Menke J, Rabacal WA, Byrne KT, Iwata Y, Schwartz MM, Stanley ER et al. Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis. JAm Soc Nephrol 2009; 20: 2581-2592.
25. Qiao JH, Tripathi J, Mishra NK, Cai Y, Tripathi S, Wang XP et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997; 150: 1687-1699. (Pubitemid 27193816)
26. Rajavashisth T, Qiao JH, Tripathi S, Tripathi J, Mishra N, Hua M et al. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor- deficient mice. J Clin Invest 1998; 101: 2702-2710. (Pubitemid 28294579)
27. Szperl M, Ansari AA, Urbanowska E, Szwech P, Kalinski P, Wiktor-Jedrzejczak W. Increased resistance of CSF-1-deficient, macrophage-deficient, TNF alpha-deficient, and IL-1 alpha-deficient op/op mice to endotoxin. Ann N Y Acad Sci 1995; 762: 499-501.
28. Lim AK, Ma FY, Nikolic-Paterson DJ, Thomas MC, Hurst LA, Tesch GH. Antibody blockade of c-fms suppresses the progression of inflammation and injury in early diabetic nephropathy in obese db/db mice. Diabetologia 2009; 52: 1669-1679.
29. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8: 533-544. (Pubitemid 351913679)
30. Conway JG, Pink H, Bergquist ML, Han B, Depee S, Tadepalli S et al. Effects of the c FMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy) benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats. JPharmacol Exp Ther 2008; 326: 41-50. (Pubitemid 351872132)
31. Rahman MM, Kukita A, Kukita T, Shobuike T, Nakamura T, Kohashi O. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 2003; 101: 3451-3459. (Pubitemid 36868944)
32. Sasmono RT, Oceandy D, Pollard JW, Tong W, Pavli P, Wainwright BJ et al. A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood 2003; 101: 1155-1163. (Pubitemid 36139391)
33. Nakamura T, Kukita T, Shobuike T, Nagata K, Wu Z, Ogawa K et al. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. JImmunol 2005; 175: 5809-5816. (Pubitemid 41508065)
34. Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappa B activation. J Biol Chem 2006; 281: 5612-5622. (Pubitemid 43847658)
35. Cantley MD, Fairlie DP, Bartold PM, Rainsford KD, Le GT, Lucke AJ et al. Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro. J Cell Physiol 2011; 226: 3233-3241.
36. Pham L, Kaiser B, Romsa A, Schwarz T, Gopalakrishnan R, Jensen ED et al. HDAC3 and HDAC7 have opposite effects on osteoclast differentiation. J Biol Chem 2011; 286: 12056-12065.
37. Aung HT, Schroder K, Himes SR, Brion K, van Zuylen W, Trieu A et al. LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEBJ 2006; 20: 1315-1327. (Pubitemid 44943839)
38. Halili MA, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C et al. Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol 2010; 87: 1103-1114.
39. Laribee RN, Klemsz MJ. Loss of PU.1 expression following inhibition of histone deacetylases. J Immunol 2001; 167: 5160-5166. (Pubitemid 33009752)
40. Sester DP, Beasley SJ, Sweet MJ, Fowles LF, Cronau SL, Stacey KJ et al. Bacterial/Cp G DNA down-modulates colony stimulating factor-1 receptor surface expression on murine bone marrow-derived macrophages with concomitant growth arrest and fac-tor-independent survival. J Immunol 1999; 163: 6541-6550.
41. Ceponis A, Konttinen YT, Imai S, Tamulaitiene M, Li TF, Xu JW et al. Synovial lining, endothelial and inflammatory mononuclear cell proliferation in synovial membranes in psoriatic and reactive arthritis: A comparative quantitative morphometric study. Br J Rheumatol 1998; 37: 170-178.
42. Rekhter MD, Gordon D. Active proliferation of different cell types, including lympho-cytes, in human atherosclerotic plaques. Am J Pathol 1995; 147: 668-677.
43. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N et al. Local macrophage proliferation, ratherthan recruitmentfrom theblood, isa signatureof TH2 inflammation. Science 2011; 332: 1284-1288.
44. Grabiec AM, Krausz S, de Jager W, Burakowski T, Groot D, Sanders ME et al. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol 2010; 184: 2718-2728.
45. Pagliari LJ, Perlman H, Liu H, Pope RM. Macrophages require constitutive NF-kappa B activation to maintain A1 expression and mitochondrial homeostasis. Mol Cell Biol 2000; 20: 8855-8865. (Pubitemid 32245918)
46. Mercado N, Thimmulappa R, Thomas CM, Fenwick PS, Chana KK, Donnelly LE et al. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem Biophys Res Commun 2011; 406: 292-298.
47. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003; 307: 720-728. (Pubitemid 37310689)
48. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBOJ 2002; 21: 2672-2681. (Pubitemid 34619383)
49. Wilting RH, Yanover E, Heideman MR, Jacobs H, Horner J, van der Torre J et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoi-esis. EMBOJ 2010; 29: 2586-2597.
50. Yamaguchi T, Cubizolles F, Zhang Y, Reichert N, Kohler H, Seiser C et al. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev 2010; 24: 455-469.
51. Song W, Tai YT, Tian Z, Hideshima T, Chauhan D, Nanjappa P et al. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia 2011; 25: 161-168.
52. Bode KA, Schroder K, Hume DA, Ravasi T, Heeg K, Sweet MJ et al. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 2007; 122: 596-606. (Pubitemid 350075958)
53. Kim ES, Lee JK. Histone deacetylase inhibitors decrease the antigen presenting activity of murine bone marrow derived dendritic cells. Cell Immunol 2010; 262: 52-57.
54. Misaki K, Morinobu A, Saegusa J, Kasagi S, Fujita M, Miyamoto Y et al. Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic phenotype and ameliorates arthritis in SKG mice. Arthritis Res Ther 2011; 13: R77.
55. Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007; 109: 1123-1130. (Pubitemid 46220659)
56. Singh N, Thangaraju M, Prasad PD, Martin PM, Lambert NA, Boettger T et al. Blockade of dendritic cell development by bacterial fermentation products butyrate and propio-nate through a transporter (Slc5a8)-dependent inhibition of histone deacetylases. J Biol Chem 2010; 285: 27601-27608.
57. Nascimento CR, Freire-de-Lima CG, da Silva de Oliveira A, Rumjanek FD, Rumjanek VM. The short chain fatty acid sodium butyrate regulates the induction of CD1a in developingdendriticcells. Immunobiology 2011; 216: 275-284.
58. Nencioni A, Beck J, Werth D, Grunebach F, Patrone F, Ballestrero A et al. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res 2007; 13: 3933-3941. (Pubitemid 47037601)
59. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M et al. The histone deacetylase HDAC11 regulates theexpression of interleukin 10and immunetolerance. Nat Immunol 2009; 10: 92-100.
60. Duvic M, Vu J. Vorinostat: A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007; 16: 1111-1120. (Pubitemid 47074165)
61. Bishton MJ, Harrison SJ, Martin BP, Mc Laughlin N, James C, Josefsson EC et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 2011; 117: 3658-3668.
62. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011; 117: 5827-5834.
63. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 718-728. (Pubitemid 34742100)
64. Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: A Wisconsin Oncology Network phase II study. J Thorac Oncol 2009; 4: 522-526.
65. Yang LP. Romidepsin: in the treatment of T-cell lymphoma. Drugs 2011; 71: 1469-1480.
66. Kankaanranta H, Janka-Junttila M, Ilmarinen-Salo P, Ito K, Jalonen U, Ito M et al. Histone deacetylase inhibitors induceapoptosis in human eosinophils and neutrophils. J Inflamm (Lond) 2010; 7: 9.
67. Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT, Kim DY. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 2005; 35: 89-96. (Pubitemid 40188276)
68. Ishihara K, Hong J, Zee O, Ohuchi K. Possible mechanism of action of the histone deacetylase inhibitors for the induction of differentiation of HL-60 clone 15 cells into eosinophils. Br JPharmacol 2004; 142: 1020-1030. (Pubitemid 39037052)
69. Ishihara K, Takahashi A, Kaneko M, Sugeno H, Hirasawa N, Hong J et al. Differentiation of eosinophilic leukemia Eo L-1 cells into eosinophils induced by histone deacetylase inhibitors. Life Sci 2007; 80: 1213-1220. (Pubitemid 46329010)
70. Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: geneticdefectsofapoptosispathways. Cell Death Differ 2003; 10: 124-133.
71. Otterson GA, Hodgson L, Pang H, Vokes EE. Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lungcancer (Cancerand Leukemia Group B 30304). J Thorac Oncol 2010; 5: 1644-1648.
72. Dequiedt F, Kasler H, Fischle W, Kiermer V, Weinstein M, Herndier BG et al. HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediatedapoptosis. Immunity 2003; 18: 687-698. (Pubitemid 36588585)
73. Dequiedt F, Van Lint J, Lecomte E, Van Duppen V, Seufferlein T, Vandenheede JR et al. Phosphorylation of histone deacetylase 7 by protein kinase D mediates Tcell receptor-induced Nur77 expression and apoptosis. J Exp Med 2005; 201: 793-804. (Pubitemid 40395123)
74. Parra M, Kasler H, Mc Kinsey TA, Olson EN, Verdin E. Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation. J Biol Chem 2005; 280: 13762-13770. (Pubitemid 40517272)
75. Kasler HG, Verdin E. Histone deacetylase 7 functions as a key regulator of genes involved in both positiveand negativeselection ofthymocytes. Mol Cell Biol 2007; 27: 5184-5200. (Pubitemid 47068292)
76. Kasler HG, Young BD, Mottet D, Lim HW, Collins AM, Olson EN et al. Histone deacetylase 7 regulates cell survival and TCR signaling in CD4/CD8 double-positive thymocytes. JImmunol 2011; 186: 4782-4793.
77. Moreira JM, Scheipers P, Sorensen P. The histone deacetylase inhibitor Trichostatin A modulates CD4+ Tcell responses. BMC Cancer 2003; 3: 30.
78. Johnson J, Pahuja A, Graham M, Hering B, Hancock WW, Bansal-Pakala P. Effects of histone deacetylase inhibitor SAHAon effector and FOXP3+regulatory Tcells in rhesus macaques. Transplant Proc 2008; 40: 459-461. (Pubitemid 351419219)
79. Reilly CM, Mishra N, Miller JM, Joshi D, Ruiz P, Richon VM et al. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol 2004; 173: 4171-4178. (Pubitemid 39280783)
80. Navarro MN, Goebel J, Feijoo-Carnero C, Morrice N, Cantrell DA. Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes. Nat Immunol 2011; 12: 352-361.
81. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13: 1299-1307. (Pubitemid 350073591)
82. Reilly CM, Thomas M, Gogal Jr R, Olgun S, Santo A, Sodhi R et al. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunityin NZB/WF1 mice. JAutoimmun 2008; 31: 123-130.
83. Lucas JL, Mirshahpanah P, Haas-Stapleton E, Asadullah K, Zollner TM, Numerof RP. Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. Cell Immunol 2009; 257: 97-104.
84. Saouaf SJ, Li B, Zhang G, Shen Y, Furuuchi N, Hancock WW et al. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp Mol Pathol 2009; 87: 99-104.
85. de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 2010; 138: 583-594.
86. Zhang ZY,Zhang Z,Schluesener HJ MS-275,anhistonedeacetylaseinhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis. Neuroscience 2010, 169, 370-377.
87. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25high Foxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008; 112: 2340-2352.
88. Akimova T, Ge G, Golovina T, Mikheeva T, Wang L, Riley JL et al. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol 2010; 136: 348-363
89. de Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol 2011; 31: 2066-2078.
90. Beier UH, Wang L, Bhatti TR, Liu Y, Han R, Ge G et al. Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival. Mol Cell Biol 2011; 31: 1022-1029.
91. Grausenburger R, Bilic I, Boucheron N, Zupkovitz G, El-Housseiny L, Tschismarov R et al. Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J Immunol 2010; 185: 3489-3497.
92. Yan K, Cao Q, Reilly CM, Young NL, Garcia BA, Mishra N. Histone Deacetylase 9 Deficiency Protects against Effector T Cell-mediated Systemic Autoimmunity. J Biol Chem 2011; 286: 28833-28843.
93. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834-840.